REVOLVING LINE OF CREDIT NOTECredit Note • July 7th, 2020 • Biolargo, Inc. • Chemicals & allied products • California
FOR VALUE RECEIVED, Clyra Medical Technologies, Inc., a California corporation (“Borrower”) promises to pay to Vernal Bay Capital Group, LLC, a California limited liability company (the “Lender”), or to order, the principal sum of One Million Dollars ($1,000,000) or the aggregate unpaid principal amount of all Advances made by Lender to Borrower pursuant to the terms of a Revolving Line of Credit Agreement dated June 30, 2020 (the “Loan Agreement”), together with interest thereon from the date each advance is made until paid in full. All capitalized terms used in this Revolving Line of Credit Note (this “Promissory Note”) shall have the meaning given to them in the Loan Agreement.
REVOLVING LINE OF CREDIT AGREEMENTRevolving Line of Credit Agreement • July 7th, 2020 • Biolargo, Inc. • Chemicals & allied products • California
This Revolving Line of Credit Agreement is made and entered into this 30th day of June, 2020 (the “Effective Date”), by and between Vernal Bay Capital Group, LLC, a California limited liability company (the “Lender”), and Clyra Medical Technologies, Inc., a California corporation (“Borrower”).
SECURITY AGREEMENTSecurity Agreement • July 7th, 2020 • Biolargo, Inc. • Chemicals & allied products • California
This SECURITY AGREEMENT is dated as of June 30, 2020, and made by and between Clyra Medical Technologies, Inc., a California corporation, with offices at 4830 West Kennedy Blvd., Ste. 600, Tampa, FL 33069 (“Debtor”), and Vernal Bay Capital Group, LLC, a California limited liability company, with offices at 1601 Dove Street, Suite 250, Newport Beach CA 92660 (“Secured Party”), with reference to the following recitals:
SECOND AMENDMENT TO LICENSE AGREEMENTLicense Agreement • July 7th, 2020 • Biolargo, Inc. • Chemicals & allied products
THIS SECOND AMENDMENT TO LICENSE AGREEMENT (“Amendment”) is made and entered into as of this June 30, 2020, by and between BIOLARGO, INC., a Delaware corporation, and its wholly owned subsidiary BioLargo Life Technologies, Inc., a California corporation (collectively, “Licensor”), and CLYRA MEDICAL TECHNOLOGIES, INC., a California corporation (“Licensee”), with respect to the following:
SECOND AMENDMENT TO CONSULTING AGREEMENTConsulting Agreement • July 7th, 2020 • Biolargo, Inc. • Chemicals & allied products
THIS SECOND AMENDMENT TO CONSULTING AGREEMENT (“Amendment”) is made and entered into as of this June 30, 2020, by and between Beach House Consulting, LLC, a Minnesota limited liability company (“Consultant”) and Clyra Medical Technologies, Inc., a California corporation (“Client”), with respect to the following:
